Power Law company profile

Fusion Pharmaceuticals

Biotech & Life Sciences · Hamilton, Canada · Founded 2014 · IPO 2020 Unicorn

Targeted alpha therapeutics (TAT) for the treatment of chemotherapy resistant cancers

Valuation

$1.68B

Market cap · 2026

Revenue

$2.1M

Latest reported FY

Featured in Unicorn$1B+ valuation tier · Power Law dataset 2026

Investors

13 investors on Fusion Pharmaceuticals's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Seed 1 investor entered at this stage

FACIT (Fight Against Cancer Innovation Trust)

Series A 8 investors entered at this stage

Johnson & Johnson Development Corporation

Genesys Capital

Seroba Life Sciences

Varian Medical Systems

TPG Biotech

Adams Street Partners

HealthCap

Johnson & Johnson Innovation

Series B+ 4 investors entered at this stage

OrbiMed

Pivotal Life Sciences

Rock Springs Capital

Perceptive Advisors

Global footprint

Where Fusion Pharmaceuticals has talent and traffic

Workforce by country

5 countries with
team presence

🇨🇦 Canada56.9%

🇺🇸 United States39%

🇮🇳 India2.9%

🇬🇧 United Kingdom1%

🇪🇬 Egypt1%

5 countries shown

Web traffic by country

5.2K monthly visits
across markets

🇨🇦 Canada57.7%

🇺🇸 United States42.3%

Top 2 markets shown

Market sentiment

What the market is saying about Fusion Pharmaceuticals

An AI-synthesized read of the highest-engagement posts about Fusion Pharmaceuticals on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Fusion Pharmaceuticals on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles